Skip to main content

European Network for the identification and validation of Antigens and biomarkers in Cancer and their application in clinical Tumour immunology

Objective

ENACT aims to identify markers of response and tumour antigens that associate with ovarian and prostate cancer and melanoma progression and resistance to immunotherapy. Prospective clinical material will be collected during the life of the programme and new and existing tumour tissue, PBMC and serum banks will be available for use in the study. This common resource of material will be distributed to partners for the immunological, genomic, biochemical and proteomic analysis of tumour cells and host response(s) to immunotherapy. The results will be subjected to bioinformatic analysis in the context of clinical outcome of vaccine-based immunotherapy trials from 5 European clinical centres. Analysis of the results in the context of gender, will allow prominent inter- and intra- tumour/host biomarkers to be identified and translated back into clinical practice. The combined clinical and scientific expertise of the consortium provides added value and links with two on- going 5th Framework cancer programmes that will allow immediate access to melanoma patient data, tumour tissue and cell lines. This study promotes interdisciplinary translational research, which will offer a leading role to partners in 3 Eastern European NAS countries and in SMEs, and will provide a unique technology and science-driven platform for future expansion. We (the consortium) have extensive experience in the management and operation of 3rd-5th Framework projects and this current programme of research builds on previous experience and collaboration by many of the partners, but also increases the repertoire of scientific expertise by the inclusion of new partners, whose research skills are complimentary to the aims of ENACT.

Call for proposal

FP6-2002-LIFESCIHEALTH
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

THE NOTTINGHAM TRENT UNIVERSITY
Address
Burton Street
Nottingham
United Kingdom

Participants (13)

MEDICAL UNIVERSITY HOSPITAL "ALEXANDROVSKA"
Bulgaria
Address
Georgy Sofiiski 1
Sofia
EBERHARD-KARLS-UNIVERSITÄT TÜBINGEN
Germany
Address
Wilhelmstr. 5
Tübingen
KAROLINSKA INSTITUTET
Sweden
Address
Karolinska Institutet
Stockholm
JAGIELLONIAN UNIVERSITY, MEDICAL COLLEGE
Poland
Address
Sw. Anny 12
Krakow
UNIVERSITY OF LATVIA, BIOMEDICAL RESEARCH AND STUDY CENTRE
Latvia
Address
Ratsupites St 1
Riga
FUNDACIÓN VIRGEN DE LAS NIEVES
Spain
Address
C/ Dr. Azpitarte S/n. Edificio Licinio De La Fuente
Granada
DEUTSCHES KREBSFORSCHUNGSZENTRUM (GERMAN CANCER RESEARCH CENTER)
Germany
Address
Im Neuenheimer Feld 280
Heidelberg
THE NORWEGIAN RADIUM HOSPITAL HF
Norway
Address
Montebello
Oslo
THE ANTHONY NOLAN TRUST
United Kingdom
Address
The Royal Free Hospital Pond St
Hampstead, London
LOREUS LIMITED
United Kingdom
Address
Gervase J-block, Clifton Campus, Clifton Lane,
Nottingham
A'PESYP OF ATTICA-SAINT SAVAS CANCER HOSPITAL-CANCER IMMUNOLOGY AND IMMUNOTHERAPY CENTER
Greece
Address
3,Zacharof Str
Athens
ONYVAX LTD
United Kingdom
Address
St Georges Hospital Medical School,cranmer Terrace
London
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
101 Rue De Tolbiac
Paris